

VISCHER ADVISES FORTY51 VENTURES IN THE CLOSING OF ITS FIRST FUND

Posted on 12 September 2022



Category: [Banking & Finance](#)

Tags: [life sciences](#), [Matthias Staehelin](#), [Nadia Tarolli](#), [ria gurtner](#), [Slider](#), [Stefan Grieder](#), [Vischer](#)



VISCHER has advised **Forty51 Ventures**, a Biotech venture capital firm, on its first fund, Forty51 Ventures Fund I which has raised USD 43 million in a first closing and is domiciled in Luxembourg. VISCHER has supported, in particular, regarding the setting up of Forty51 Advisory, in Basel which renders advisory services to the Fund. As well they has advice on the regulatory requirements for promoting the Fund in Switzerland and on the Swiss tax aspects of the structure of Forty51 Ventures.

FORTY51's core strategy focuses on company formation and early stage investments in Biotech with geographic emphasis on Switzerland, France and Germany. FORTY51 Ventures will lead or co-lead early rounds (Seed and Series A) of its growing portfolio which will include both academic and Pharma spin-outs.

The team was led by **Stefan Grieder** (partner, banking & finance, pictured) with **Matthias Staehelin** (partner, corporate/m&a), **Ria Gurtner** (associate, banking & finance) and **Nadia Tarolli** (partner, tax).

Other advisors were Dechert for Luxembourg and Barnes & Thornburg for USA.